Nivolumab Plus Ipilimumab Improves On Chemo In Previously Untreated Msi-H/Dmmr Mcrc

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC

CheckMate 8HW: first-line nivolumab plus ipilimumab in MSI-H/dMMR mCRC

CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed...

Dr. Andre on Nivolumab Plus Ipilimumab in dMMR/MSI-H mCRC

Nivolumab/Ipilimumab Combination Data Promising in MSI-H/dMMR mCRC

Targeted Oncology

HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRC

Dual checkpoint inhibitors for MSI high colorectal cancer

OncBrothers: Practice-Changing Cancer Discussions

Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups

Pembrolizumab improves on chemo in MSI-H/dMMR mCRC

Nivolumab Plus Ipilimumab vs Chemotherapy in Unresectable Mesothelioma

Remaining questions for the treatment of patients with MSI/dMMR mCRC with immunotherapy

Promising CheckMate-142 Data for Second-Line Ipilimumab Plus Nivolumab in mCRC

Targeted Oncology

Nivolumab plus low-dose ipilimumab promising for treatment-naïve MSI-high mCRC | Heinz-Josef Lenz

Medicine Matters oncology

CheckMate 8HW: Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Colorectal Cancer

GI Oncology Now

Nivolumab and Ipilimumab Combination in Frontline mCRC

Targeted Oncology

CheckMate 743: First-line nivolumab plus ipilimumab vs chemotherapy in patients with unresectabl...

Moving Forward With Results From CheckMate-142 in MSI-H mCRC

Targeted Oncology

ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer